Immix Biopharma, Inc.
NASDAQ:IMMXBiotechnology
+$0.09 today
- Market cap
- $595.91M
- Beta
- 0.10
- P/E (TTM)
- -10.1
- EPS (TTM)
- -$0.91
Volume 0.88M
Average 1.07M
IMMX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Immix Biopharma, Inc.NASDAQ: IMMX
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 397.8% from a year ago
Cash & equivalents stood at $79.25M at the end of Q1 FY2026, up 397.8% from a year earlier and down 15.6% from the prior quarter. Over 3 fiscal years it compounded at +91.2% a year.
Context
- Cash & equivalents amounted to 82.7% of total assets at the end of Q1 FY2026, up 2.7 pp from a year earlier.
- Cash & equivalents increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +397.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 93.93M USD
- Year-over-year change
- +431.2%
- 4-year CAGR
- +51.9%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 93.93M | +431.2% |
| FY2024 | 2024-12-31 | 17.68M | +1.0% |
| FY2023 | 2023-12-31 | 17.51M | +30.3% |
| FY2022 | 2022-12-31 | 13.44M | -23.8% |
| FY2021 | 2021-12-31 | 17.64M | — |
Cash & Equivalents vs competitors
How IMMX compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +397.8% is the 4th highest of 11, against a peer median of -32.3%.
- Cash & equivalents amounts to 82.7% of total assets for IMMX, versus a peer median of 40.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Aug 2026 | $720.24M USD | +818.2% | +56.5% | 60.3% | |
| Jun 2026 | €387.99M EUR | +536.6% | +167.6% | 83.9% | |
| Mar 2026 | $186.63M USD | +1204.7% | -47.5% | 98.4% | |
| Jun 2026 | $150M USD | -39.5% | +2.5% | 16.2% | |
| Mar 2026 | $79.25M USD | +397.8% | +91.2% | 82.7% | |
| Dec 2025 | A$72.75M AUD | -1.5% | -5.5% | 49.4% | |
| Mar 2026 | $66.52M USD | -54.3% | -19.3% | 30.5% | |
NBPNovaBridge Biosciences | Dec 2025 | $30.11M USD | -94.0% | -78.9% | 80.8% |
| Mar 2026 | $28.83M USD | -39.4% | -59.7% | 8.0% | |
| Sep 2026 | $26.95M USD | -25.2% | -0.6% | 3.7% | |
| Mar 2026 | $8.54M USD | -64.5% | +2.2% | 17.4% | |
| Peer median (excluding IMMX) | — | -32.3% | -3.1% | 40.0% | |
Competitors are the stored peer set for IMMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 17.64M | 13.44M | 17.51M | 17.68M | 93.93M |
| Short-term Investments | 0 | 0 | 0 | 0 | 6.48M |
| Net Receivables | 25.72K | 255.71K | 1.17M | 1.97M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 516.19K | 78.07K | 44.58K | 32.27K | 150.72K |
| Total Current Assets | 18.19M | 14.9M | 19.79M | 20.2M | 101.24M |
| Property, Plant & Equipment (Net) | 5.7K | 3.56K | 50.18K | 2.73M | 3.49M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | (0) | 6.72K | 87.23K | 20.42K | 114.05K |
| Total Non-current Assets | 5.7K | 10.28K | 137.41K | 2.75M | 3.6M |
| Total Assets | 18.19M | 14.91M | 19.93M | 22.95M | 104.84M |
| Account Payables | 142.94K | 143.07K | 1.43M | 5.39M | 5.44M |
| Short-term Debt | 50K | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 658.16K | 0 |
| Total Current Liabilities | 202.04K | 1.27M | 3.72M | 8.69M | 10.11M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 475K | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 475K | 0 | 1.01M | 933.63K |
| Total Liabilities | 202.04K | 1.75M | 3.72M | 9.7M | 11.04M |
| Common Stock | 1.32K | 1.4K | 2K | 2.76K | 5.3K |
| Retained Earnings | (29.76M) | (37.99M) | (53.41M) | (75.02M) | (104.46M) |
| Accumulated OCI | 125.41K | 87.02K | 134.67K | (1.06K) | 60.16K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | (201.74K) | 0 | 0 |
| Total Equity | 17.99M | 13.16M | 16.2M | 13.25M | 93.8M |
| Total Debt | 50K | 0 | 0 | 1.07M | 1.07M |
| Net Debt | (17.59M) | (13.44M) | (17.51M) | (16.61M) | (92.86M) |
Immix Biopharma, Inc.
NASDAQ:IMMX
Intrinsic Alpha fair value
Locked
Current Price
$7.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.